Tissue Regenix Group plc
Company Profile
Company website
Sector
Pharmaceuticals & Biotechnology (Biotechnology)
Description
Tissue Regenix Group plc (AIM: TRX) is a pioneering, international medical technology company focused on the development of regenerative products using two platform technologies, dCELL®, addressing soft tissue needs, and BioRinse™, providing inductive bone allografts.
.png "TRX - Hardman Co - Turning profitable and cash-generative (05.04.23)")
Investor Access
19
Mar
Event information
The Company will be announcing its final results for the year ended 31 December 2023 on Tuesday 19 March 2024
Investors can sign up to Investor Meet Company for free and add to meet Tissue Regenix Group plc here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investorVenue
Online
Time
Tuesday 19 March 2024 at 11am
Financial Calendar
| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | June |
| Interim Results* | 5 September |
| AGM* | June |
* Months based on previous announcements of this kind
